Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Main trialPhase 2
- “This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to severe alopecia areata, defined as having a \>50% loss of terminal hair on the scalp. The study has three periods: * 30-Day Screening Period * 3-Month Treatment Period * 3-Month Follow-up Period The study will be conducted at approximately 15-20 clinical sites in the United States.”In the company’s words, NCT03532958 on ClinicalTrials.gov
Other drugs for Alopecia Areata
- RitlecitinibPfizer · Phase 3
- DeuruxolitinibSun Pharma · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Withdrawn | Nov 2022 | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026